CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
10.38
-0.36 (-3.35%)
Nov 21, 2024, 1:59 PM EST - Market open
CorMedix Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for CorMedix stock have an average target of 15.2, with a low estimate of 9.00 and a high estimate of 19. The average target predicts an increase of 46.44% from the current stock price of 10.38.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CorMedix stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $10 → $18 | Strong Buy | Maintains | $10 → $18 | +73.41% | Oct 31, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $12 → $17 | Strong Buy | Maintains | $12 → $17 | +63.78% | Oct 22, 2024 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | +25.24% | Aug 26, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $9 | Buy | Reiterates | $9 | -13.29% | Aug 15, 2024 |
| Needham | Needham | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | -3.66% | Aug 15, 2024 |
Financial Forecast
Revenue This Year
32.71M
Revenue Next Year
123.57M
from 32.71M
Increased by 277.75%
EPS This Year
-0.49
from -0.91
EPS Next Year
0.49
from -0.49
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 35.4M | 182.8M | 206.2M | ||
| Avg | 32.7M | 123.6M | 186.8M | ||
| Low | 30.2M | 85.5M | 166.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 458.9% | 66.9% | ||
| Avg | - | 277.8% | 51.2% | ||
| Low | - | 161.4% | 34.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.48 | 0.99 | 1.58 | ||
| Avg | -0.49 | 0.49 | 1.42 | ||
| Low | -0.50 | 0.23 | 1.25 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 223.8% | ||
| Avg | - | - | 191.0% | ||
| Low | - | - | 156.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.